抗 LAG-3 增强 CD8 T 细胞效应功能。

Anti-LAG-3 boosts CD8 T cell effector function.

机构信息

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA; Program in Immunology, Harvard Medical School, Boston, MA, USA.

Program in Immunology, Harvard Medical School, Boston, MA, USA; Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.

出版信息

Cell. 2024 Aug 8;187(16):4144-4146. doi: 10.1016/j.cell.2024.07.004.

DOI:10.1016/j.cell.2024.07.004

PMID:39121844

Abstract

LAG-3 is the third immune checkpoint pathway successfully targeted for cancer therapy. Although ineffective as a monotherapy, combination of LAG-3 and PD-1 blockade improves survival from advanced melanoma. In this issue of Cell, two studies in mice and a human clinical trial provide insights on LAG-3 in immune regulation.

摘要

LAG-3 是第三个成功针对癌症治疗的免疫检查点通路。尽管作为单一疗法无效，但 LAG-3 和 PD-1 阻断的联合治疗可改善晚期黑色素瘤的生存。在本期《Cell》中，两项小鼠研究和一项人类临床试验提供了 LAG-3 在免疫调节中的见解。